Dignify Therapeutics LLC

Research Triangle Park, NC · Founded 2013 · Biotech · Private

On-demand pharmaceutical compounds that trigger bowel and bladder emptying

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · dignifytherapeutics.com

Sector: Biotech
Headquarters: Research Triangle Park, NC
Founded: 2013
Latest Form D: $800K, Sep 2026
Total capital: $23.5M

Federal grants: $22.6M; 33 awards · 2015–2025; Rank in peer group#44 of 514
Private capital raised: $900K; 2 Form D · last Sep 2026; 1 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 4; 15 pending · first 2018; Rank in peer group#85 of 514

Capital timeline

Latest events

Sep 2026Private capital raisedForm D · SEC · 2nd filing$800K
Aug 2025Federal grantHealth and Human S · Phase I · Novel treatment for urinary incontinence and overactive bladder symptoms in the elderly$110K
Sep 2024Federal grantHealth and Human S · Phase I · Therapy for Fecal Incontinence and FecalUrgency$391K
Sep 2024Federal grantHealth and Human S · Phase I · Novel treatment for urinary incontinence and overactive bladder symptoms in the elderly$390K
Mar 2023Federal grantHealth and Human S · Phase I · Preclinical and Early Clinical Development of a Novel Drug for On-Demand Voiding$542K
Jun 2022Federal grantHealth and Human S · Phase II · Pudendal neuromodulation for urinary and fecal incontinence and sphincter dyssynergia$50K
Aug 2021Federal grantHealth and Human S · Phase II · Pudendal neuromodulation for urinary and fecal incontinence and sphincter dyssynergia$431K
Oct 2014Private capital raisedForm D · SEC · 1st filing$100K

Show 27 earlier federal awards

Sep 2020Federal grantHealth and Human S · Phase II · Pudendal neuromodulation for urinary and fecal incontinence and sphincter dyssynergia$941K
Sep 2020Federal grantHealth and Human S · Phase I · Neurokinin-2 receptor-induced micturition and defecation in aged diabetic rats$244K
Sep 2020Federal grantHealth and Human S · Phase I · Neurokinin-2 receptor-induced micturition and defecation in aged diabetic rats$296K
Aug 2020Federal grantHealth and Human S · Phase I · Examination of a novel potential therapy for autonomic dysreflexia$395K
Mar 2020Federal grantHealth and Human S · Phase II · Preclinical characterization of a novel neuropeptide for inducing "on-demand" voiding$3M
Sep 2019Federal grantHealth and Human S · Phase I · Intrarectal mechanoreceptor sensitization to induce defecation after spinal injury$300K
Sep 2019Federal grantHealth and Human S · Phase I · Pudendal neuromodulation for incontinence and sphincter dyssynergia after spinal injury$269K
Apr 2019Federal grantHealth and Human S · Phase II · Development of a first-in-class therapeutic for producing 'on-demand' voiding$999K
Jul 2018Federal grantHealth and Human S · Phase II · An optimized NK2R agonist for 'on-demand' voiding$615K
Jun 2018Federal grantHealth and Human S · Phase II · Development of a first-in-class therapeutic for producing 'on-demand' voiding$1M
May 2018Federal grantHealth and Human S · Phase II · Development of a first-in-class therapeutic for producing 'on-demand' voiding$2M
Sep 2017Federal grantHealth and Human S · Phase II · An optimized NK2R agonist for 'on-demand' voiding$1.8M
Sep 2017Federal grantHealth and Human S · Phase II · An optimized NK2R agonist for 'on-demand' voiding$1.2M
Aug 2017Federal grantHealth and Human S · Phase I · A neurokinin receptor agonist to treat underactive bladder in the elderly$300K
Aug 2017Federal grantHealth and Human S · Phase II · Development of a first-in-class therapeutic for producing 'on-demand' voiding$300K
Aug 2017Federal grantHealth and Human S · Phase II · Delivery of peptides for inducing voiding associated with neurological retention$411K
Jul 2017Federal grantHealth and Human S · Phase II · Development of a treatment for voiding dysfunction in spinal cord injured patients$682K
Sep 2016Federal grantHealth and Human S · Phase II · Delivery of peptides for inducing voiding associated with neurological retention$1.4M
Sep 2016Federal grantHealth and Human S · Phase I · Identification of an optimized NK2R agonist for 'on-demand' voiding$276K
Sep 2016Federal grantHealth and Human S · Phase II · Delivery of peptides for inducing voiding associated with neurological retention$953K
Sep 2016Federal grantHealth and Human S · Phase I · Identification of an optimized NK2R agonist for 'on-demand' voiding$276K
Jul 2016Federal grantHealth and Human S · Phase II · Development of a treatment for voiding dysfunction in spinal cord injured patients$1.5M
Jul 2016Federal grantHealth and Human S · Phase II · Development of a treatment for voiding dysfunction in spinal cord injured patients$818K
May 2015Federal grantHealth and Human S · Phase I · Development of potential delivery methods for treating voiding dysfunction associated with SCI$199K
Apr 2015Federal grantHealth and Human S · Phase I · Development of potential delivery methods for treating voiding dysfunction associated with SCI$199K
Apr 2015Federal grantHealth and Human S · Phase I · Delivery of peptides for inducing voiding associated with neurological retention$225K
Apr 2015Federal grantHealth and Human S · Phase I · Delivery of peptides for inducing voiding associated with neurological retention$225K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#44 · top 9%
Granted patents#85 · top 17%
Linked publications#18 · top 4%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Karl B ThorResearcherExecutive Officer, Director, PromoterLinked by 1 patent · $10.5M in grants as PI
Edward C BurgardResearcherExecutive Officer, Director, PromoterLinked by $3.6M in grants as PI
Lesley Aura MarsonResearcherPromoterLinked by $7.4M in grants as PI
Benny WardExecutive Officer, Director, PromoterNamed in SEC Form D filings
Daniel J RiccaDirector, PromoterNamed in SEC Form D filings
Ebrahim B VersiDirector, PromoterNamed in SEC Form D filings

Show all 11 people

Florenta Aura KullmannPromoterNamed in SEC Form D filings
Fred Aura EshelmanDirectorNamed in SEC Form D filings
Mary B KatofiascPromoterNamed in SEC Form D filings
Tatyana Aura TouzovaPromoterNamed in SEC Form D filings
Venkateswarlu Aura KarichetiPromoterNamed in SEC Form D filings

What it has protected

USPTO · 4 granted of 19

Mar 28, 2024PendingCompositions And Methods For Inducing DefecationUSPTOApplication 18269973
Nov 23, 2023PendingCompositions For Inducing Urinary Voiding And DefecationUSPTOApplication 18248452
Oct 4, 2022GrantedCompositions And Methods For Inducing DefecationUSPTOUS 11,458,112

Show all 19 patent records

Compositions And Methods For Inducing DefecationMar 28, 2024 · Application 18269973Pending
Compositions For Inducing Urinary Voiding And DefecationNov 23, 2023 · Application 18248452Pending
Compositions And Methods For Inducing DefecationOct 4, 2022 · US 11,458,112Granted
Compositions For Inducing Urinary Voiding And DefecationJun 7, 2022 · US 11,352,391Granted
Method Of Treating Voiding DysfunctionMay 4, 2021 · US 10,994,134Granted
Compositions And Methods For Inducing Urinary Voiding And DefecationOct 2, 2018 · US 10,086,034Granted
Compositions For Inducing Urinary Voiding And DefecationApplication 63089268Pending
Compositions And Methods For Treating Autonomic DysreflexiaApplication 63001863Pending
Compositions And Methods For Inducing DefecationApplication PCTUS2022012220Pending
Compositions And Methods For Inducing DefecationApplication PCTUS2019042320Pending
Method Of Treating Voiding DysfunctionApplication PCTUS2019041170Pending
Method Of Treating Voiding DysfunctionApplication 62696578Pending
Compositions For Inducing Urinary Voiding And DefecationApplication PCTUS2018023466Pending
Compositions For Inducing Urinary Voiding And DefecationApplication 62561387Pending
Compositions And Methods For Inducing Urinary Voiding And DefecationApplication PCTUS2014048953Pending
Compositions For Inducing Urinary Voiding And DefecationApplication PCTUS2021054165Pending
Compositions And Methods For Treating Urinary Voiding And Defecation DysfunctionApplication 61860995Pending
Compositions And Methods For Treating Autonomic DysreflexiaApplication PCTUS2021024407Pending
Compositions And Methods For Inducing DefecationApplication 63137778Pending

Recent research by its founders

Aged and Young Adult Rats Respond Similarly to Highly Selective Neurokinin 2 Receptor Agonists That Produce Urination and Defecation Without Producing Cardiovascular Side Effects20250 cites
Corrigendum to “Recent Developments in On-Demand Voiding Therapies” [The Journal of Pharmacology and Experimental Therapeutics 390 (2024) 302-317]20250 cites
Recent Developments in On-Demand Voiding Therapies20242 cites

MAJESTIC THERAPEUTICS, LLCSimilar federal contract value in Biotech · null in contracts
149 BIO LLCSimilar federal contract value in Biotech · null in contracts
ECHELON BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
NORTHSTAR GENOMICS, LLCSimilar federal contract value in Biotech · null in contracts
NUCB1 HOLDINGS LLCSimilar federal contract value in Biotech · null in contracts
ANTEL BIOSYSTEMS, INCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.